767 related articles for article (PubMed ID: 33736690)
21. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.
Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N
Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433
[TBL] [Abstract][Full Text] [Related]
22. Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors).
Bourke JM; O'Sullivan M; Khattak MA
Med J Aust; 2016 Nov; 205(9):418-424. PubMed ID: 27809739
[TBL] [Abstract][Full Text] [Related]
23. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
Thomas S; Bae C; Joy-Ann T; Traverse W
J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
[TBL] [Abstract][Full Text] [Related]
24. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
25. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
26. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
27. [Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report].
Kurokawa M; Shimizu K; Kitabayashi R; Ogawa K; Okada Y; Kubo K; Yamaguchi D; Okubo K
Hinyokika Kiyo; 2022 Sep; 68(9):295-300. PubMed ID: 36199208
[TBL] [Abstract][Full Text] [Related]
28. [Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody].
Motoyama R; Yamakawa K; Suzuki S; Kusunoki S; Tanaka M
Rinsho Shinkeigaku; 2011 Oct; 51(10):761-4. PubMed ID: 22019868
[TBL] [Abstract][Full Text] [Related]
29. Vision loss with pembrolizumab treatment: A report of two cases.
Telfah M; Whittaker TJ; C Doolittle G
J Oncol Pharm Pract; 2019 Sep; 25(6):1540-1546. PubMed ID: 30997872
[TBL] [Abstract][Full Text] [Related]
30. Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.
Ortega Sanchez G; Jahn K; Savic S; Zippelius A; Läubli H
J Immunother Cancer; 2018 Sep; 6(1):85. PubMed ID: 30176946
[TBL] [Abstract][Full Text] [Related]
31. Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report.
Qiu G; Li S; Li B; Yang Q; Deng H; Yang Y; Xie X; Lin X; Seki N; Miura S; Shukuya T; Zhou C; Liu M
Transl Lung Cancer Res; 2022 Nov; 11(11):2346-2355. PubMed ID: 36519029
[TBL] [Abstract][Full Text] [Related]
32. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
[TBL] [Abstract][Full Text] [Related]
33. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy.
Johnson D; Patel AB; Uemura MI; Trinh VA; Jackson N; Zobniw CM; Tetzlaff MT; Hwu P; Curry JL; Diab A
Cancer Immunol Res; 2019 Jun; 7(6):860-865. PubMed ID: 30996018
[TBL] [Abstract][Full Text] [Related]
34. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
Ruf T; Kramer R; Forschner A; Leiter U; Meier F; Reinhardt L; Dücker P; Ertl C; Tomsitz D; Tietze JK; Gutzmer R; Dabrowski E; Zimmer L; Gesierich A; Zierold S; French LE; Eigentler T; Amaral T; Heinzerling L
Eur J Cancer; 2024 May; 203():114028. PubMed ID: 38652976
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab.
Eun Y; Kim IY; Sun JM; Lee J; Cha HS; Koh EM; Kim H; Lee J
Sci Rep; 2019 Oct; 9(1):14039. PubMed ID: 31575933
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
[TBL] [Abstract][Full Text] [Related]
37. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.
Jour G; Glitza IC; Ellis RM; Torres-Cabala CA; Tetzlaff MT; Li JY; Nagarajan P; Huen A; Aung PP; Ivan D; Drucker CR; Prieto VG; Rapini RP; Patel A; Curry JL
J Cutan Pathol; 2016 Aug; 43(8):688-96. PubMed ID: 27086658
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
39. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Inhibitor-Induced Myositis/Myasthenia Gravis Overlap.
Gosser C; Al Bawaliz A; Bahaj W; Chesney J; Ranjan S
Cureus; 2023 Nov; 15(11):e49007. PubMed ID: 38111441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
